Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press18010.17650/1726-9776-2010-6-3-7-11LECTUREЛЕКЦИЯTREATMENT FOR STAGE I TESTICULAR SEMINOMAЛЕЧЕНИЕ СЕМИНОМЫ ЯИЧКА I СТАДИИBurovaE. A.БулановА. А.
Russian Federation
doc.elenaburova@gmail.ruBulanovA. A.ТрякинА. А.
Russian Federation
doc.elenaburova@gmail.ruTryakinA. A.ФедянинМ. Ю.
Russian Federation
doc.elenaburova@gmail.ruFedyaninM. Yu.ТюляндинC. А.
Russian Federation
doc.elenaburova@gmail.ruTyulyandinS. A.МатвеевВ. Б.
Russian Federation
doc.elenaburova@gmail.ruMatveyevV. B.БуроваЕ. А.doc.elenaburova@gmail.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowГУ РОНЦ им. Н.Н. Блохина РАМН, Москва30092010637113007201430072014https://oncourology.abvpress.ru/oncur/article/view/180

Overall survival is about 100% in patients with stage I germinogenic testicular tumors after orchifuniculectomy, which is achieved, by applying alternative adjuvant approaches. The use of approaches, such as a follow-up, chemo- and radiotherapy, may be recommended in seminoma. The paper shows the advantages and disadvantages of these methods.

Общая выживаемость пациентов с герминогенными опухолями яичка I стадии после орхифуникулэктомии составляет почти 100%, что достигается благодаря использованию альтернативных адъювантных подходов. При семиноме может быть предложено применение таких методов лечения, как динамическое наблюдение, химио- или лучевая терапия. В статье представлены основные преимущества и недостатки данных методов.

germinogenic testicular tumorsseminomaorchifuniculectomytherapy modesгерминогенные опухоли яичкасеминомаорхифуникулэктомиявиды терапии1. Warde P., Specht L., Horwich A. et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448–52.Warde P., Specht L., Horwich A. et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448–52.2. de Wit R., Fizazi K. Controversies in the management of clinical stage I testis cancer.J Clin Oncol 2006;24:5482–90.de Wit R., Fizazi K. Controversies in the management of clinical stage I testis cancer.J Clin Oncol 2006;24:5482–90.3. Aparicio J., Germa J.R., Garcia del Muro X. et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005;23(34):8717–23.Aparicio J., Germa J.R., Garcia del Muro X. et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005;23(34):8717–23.4. Fossa S.D., Horwich A., Russel J.M. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 1999;17:1146–54.Fossa S.D., Horwich A., Russel J.M. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 1999;17:1146–54.5. Jones W.G., Fossa S.D., Mead G.M. et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23(6):1200–8.Jones W.G., Fossa S.D., Mead G.M. et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23(6):1200–8.6. Santoni R., Barbera F., Bertoni F. Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only. Br J Urol Int 2003;92:47–52.Santoni R., Barbera F., Bertoni F. Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only. Br J Urol Int 2003;92:47–52.7. Travis L.B., Fossa S.D., Schonfeld S.J. et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354–65.Travis L.B., Fossa S.D., Schonfeld S.J. et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354–65.8. Livsey J.E., Taylor B., Mobarek N. et al. Patterns of relapse following radiotherapy for stage I seminoma of the testis: implications for follow-up. Clin Oncol (R Coll Radiol) 2001;13(4):296–300.Livsey J.E., Taylor B., Mobarek N. et al. Patterns of relapse following radiotherapy for stage I seminoma of the testis: implications for follow-up. Clin Oncol (R Coll Radiol) 2001;13(4):296–300.9. Warde P., Gospodarowicz M.K., Panzarella T. et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255–62.Warde P., Gospodarowicz M.K., Panzarella T. et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255–62.10. Oliver R.T., Mead G.M., Fogarty P.J. et al. Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 2008;26 (Suppl); abstr 1.Oliver R.T., Mead G.M., Fogarty P.J. et al. Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 2008;26 (Suppl); abstr 1.11. Oliver R.T., Lore S., Ong J. Alternatives to radiotherapy in the management of seminoma. Br J Urol 1990;65:61–7.Oliver R.T., Lore S., Ong J. Alternatives to radiotherapy in the management of seminoma. Br J Urol 1990;65:61–7.12. Oliver R.T., Edmonds P.M., Ong J.Y. et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: Should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 1994;29:3–8.Oliver R.T., Edmonds P.M., Ong J.Y. et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: Should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 1994;29:3–8.13. Oliver R.T., Mason M.D., Mead G.M. et al. MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 2005;366(9482):293–300.Oliver R.T., Mason M.D., Mead G.M. et al. MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 2005;366(9482):293–300.14. Fizazi K., Auperin A., Le Moulec S. et al. Stage I seminoma: Can 18Flurorodeoxyglucose positron emission tomography (FDG-PET) predict occult dissemination? A phase II study. 2008 Genitourinary Cancers Symposium; abstr 280.Fizazi K., Auperin A., Le Moulec S. et al. Stage I seminoma: Can 18Flurorodeoxyglucose positron emission tomography (FDG-PET) predict occult dissemination? A phase II study. 2008 Genitourinary Cancers Symposium; abstr 280.